Last updated: June 24, 2026
Litigation summary for BTcP Pharma v. Teva Pharmaceuticals USA, Inc. (1:17-cv-01303): what claims are in dispute, where the case sits, and what it means for generic entry
BTcP Pharma’s patent infringement case against Teva in the District of New Jersey (case number 1:17-cv-01303) is a Hatch-Waxman Orange Book litigation matter tied to a prescribed small-molecule drug. The procedural posture and substantive claim scope are not determinable from the information provided in the prompt, so no accurate litigation-specific “what patents, what claims, what dates, what settlements” summary can be produced.
What patents are at issue in BTcP Pharma v. Teva (1:17-cv-01303)?
A complete litigation summary must identify the asserted patents, asserted claims, and Teva’s accused products (NDA/ANDA linkage). Those elements are not included in the provided input, so any patent list would be speculative.
What is the Orange Book link for the asserted patents?
Orange Book listing(s) for the reference listed drug and the ANDA filing(s) determine the exclusivity and the Paragraph IV framework. The prompt does not supply the drug identity, ANDA number, or Orange Book record, so the Orange Book linkage cannot be stated.
Which patent types are typically asserted in this posture?
Hatch-Waxman litigations can target composition-of-matter, formulation, method-of-use, and/or manufacturing/process claims. The case-specific patent types cannot be determined without the complaint, infringement contentions, or docket exhibits.
What is the case timeline in BTcP Pharma v. Teva (1:17-cv-01303)?
A timeline requires docket dates (complaint filing, TRO/PI motions, Rule 12 rulings, claim construction, summary judgment, trial dates, settlement milestones, and final judgment/mandate). The prompt does not include docket entries or dates, so a factual timeline cannot be created.
Complaint and service dates: when did the infringement fight start?
The prompt does not include the complaint filing date beyond the caption number context, so the actual filing and service dates cannot be confirmed.
Claim construction and Markman: what did the court construe?
Markman order details are essential to analyze validity and infringement. No claim construction information is provided.
Summary judgment and trial: how did the court rule?
Without docket outcomes or orders, the posture (pending vs. resolved) cannot be stated.
How strong is BTcP Pharma’s patent estate versus Teva’s defenses?
Strength analysis depends on: asserted claim scope, prior art/invalidity theories pleaded, enablement/indefiniteness issues, prosecution history, and the court’s rulings. None of this is available in the provided input.
What invalidity theories are pleaded in Teva’s answer?
Common theories include anticipation/obviousness under 35 USC 102/103, lack of written description/enablement (35 USC 112), indefiniteness, and noninfringement. Case-specific theories cannot be identified without the answer or substantive motions.
What infringement arguments does BTcP make?
Infringement arguments require claim-to-accused-product mapping (limitations, dosage form, composition parameters, and use instructions). The prompt does not provide any claim chart material.
What generic entry risks exist for Teva if BTcP Pharma’s patents fall?
Entry risk analysis must be tied to: (1) which patents survive or are invalidated, (2) whether injunctions issue, (3) whether a settlement triggers market-entry on a date, and (4) remaining exclusivities (statutory and regulatory) tied to the reference drug. The prompt provides none of these determinants.
Would a Paragraph IV finding enable early launch?
Paragraph IV litigation outcomes depend on the court’s validity and infringement determinations, plus any section 271(e)(5) timing effects. No FDA linkage, ANDA status, or judgment is provided.
If there was a settlement, what trigger date would govern?
A market-entry trigger is typically tied to a settlement agreement effective date and a specific “no earlier than” date. The prompt contains no settlement terms.
What settlement agreements or consent judgments affect market-entry timing?
Settlement analysis requires: parties’ agreement date, dismissal with prejudice vs. consent judgment, any “entry at-risk” provisions, and any remaining patent carve-outs. No settlement terms or docket disposition are provided.
Did the parties stipulate to dismissal or enter a consent judgment?
Stipulation and consent judgment outcomes are not described in the prompt.
Did the case end via judgment, appeal, or dismissal?
Final disposition cannot be stated without docket information.
What is the FDA regulatory status tied to this litigation (ANDA/NDA, exclusivity, Orange Book)?
To answer this, the following are required: the reference listed drug (RLD), the ANDA filer’s number, the Orange Book patent list, the Orange Book “expiration” dates, and any 180-day exclusivity triggers. None are provided.
Which FDA pathway was involved (ANDA 505(j) vs. others)?
This cannot be determined from the prompt.
How does regulatory exclusivity interact with patent life here?
Interaction depends on whether statutory exclusivities (new chemical entity, new clinical investigation, orphan if applicable) and 180-day exclusivity are implicated. No drug identity or Orange Book record is provided.
How does BTcP Pharma v. Teva compare with other similar Hatch-Waxman fights?
Comparison requires identification of the underlying product and the litigation’s asserted patents and outcomes, so that pattern recognition across related cases is possible. The prompt does not include the drug or patent names, so comparison cannot be grounded in facts.
Are other companies challenging the same patents?
This depends on other defendants and other ANDA filers named in related dockets. No related-case identifiers or consolidated actions are provided.
Key case artifacts typically used in litigation analysis (and what’s missing here)
A litigation analysis should anchor on primary sources:
- Complaint and asserted patents
- Infringement contentions (claim charts)
- Teva’s invalidity/noninfringement contentions
- Claim construction orders
- Summary judgment orders
- Final judgment and any injunctions
- Settlement agreement or consent judgment terms
- Appeal docket (if any)
Those artifacts are not in the prompt.
Key Takeaways
- BTcP Pharma v. Teva Pharmaceuticals USA, Inc. (1:17-cv-01303) is a patent infringement action in the District of New Jersey under a Hatch-Waxman framework.
- A litigation summary that identifies asserted patents, claim scope, court rulings, and market-entry implications cannot be produced from the information provided.
- No defensible statement can be made about outcome, settlement terms, injunctions, or generic launch risk without docket and Orange Book linkage details.
FAQs
-
What does “1:17-cv-01303” imply for Hatch-Waxman timing in the District of New Jersey?
Case number alone does not provide the asserted patents, ANDA linkage, or exclusivity dates needed to assess timing.
-
Which documents should be reviewed to determine whether BTcP Pharma’s patents were found valid?
You would review the final judgment and any summary judgment or claim construction orders, none of which are provided here.
-
How do Orange Book patent expirations control Teva’s ability to launch after litigation?
Patent-by-patent expiration and any injunction or settlement carve-outs must be known; the prompt does not specify the Orange Book entries.
-
When do Paragraph IV litigations typically produce market-entry permission for an ANDA filer?
Entry can be affected by judgment timing, dismissal/settlement terms, and remaining exclusivities; specifics require the case disposition.
-
What is the fastest way to assess whether an ongoing case blocks a generic launch?
The most direct indicators are the court’s injunction status and settlement triggers; the prompt does not include those.
References
No sources were provided in the prompt, and no specific docket, complaint, or FDA/Orange Book records were included for citation.
